Journal of perinatology : official journal of the California Perinatal Association · 2026
Magnesium sulfate for brain protection in neonatal encephalopathy: a systematic review.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mimouni Francis B, Dadon Yuval, Arad Iris, Mendlovic Joseph
Аннотация
OBJECTIVE: To evaluate the safety and efficacy of postnatal magnesium sulfate (MgSO₄) for neuroprotection in neonates with neonatal encephalopathy (NE).
STUDY DESIGN: Systematic review and meta-analysis of controlled clinical trials assessing MgSO₄ administered within 12 h of birth in term or near-term infants with NE. Databases searched included MEDLINE, Embase, and Cochrane sources.
RESULTS: Twenty-four trials were included. MgSO₄ was consistently safe, with no significant adverse hemodynamic or respiratory effects. Meta-analyses demonstrated improved short-term outcomes, including reduced seizure occurrence, improved neurological status at discharge, and earlier establishment of feeding. No significant reduction in mortality was observed. Evidence regarding long-term neurodevelopmental outcomes was extremely limited. Most pre-therapeutic hypothermia studies demonstrated favorable short-term neurological or clinical outcomes. Studies conducted alongside therapeutic hypothermia have not reported long-term outcomes.
CONCLUSION: Postnatal MgSO₄ is safe and associated with improved short-term clinical outcomes in neonates with NE. However, absence of long-term benefit and limited evidence in the era of therapeutic hypothermia preclude routine clinical use.
STUDY DESIGN: Systematic review and meta-analysis of controlled clinical trials assessing MgSO₄ administered within 12 h of birth in term or near-term infants with NE. Databases searched included MEDLINE, Embase, and Cochrane sources.
RESULTS: Twenty-four trials were included. MgSO₄ was consistently safe, with no significant adverse hemodynamic or respiratory effects. Meta-analyses demonstrated improved short-term outcomes, including reduced seizure occurrence, improved neurological status at discharge, and earlier establishment of feeding. No significant reduction in mortality was observed. Evidence regarding long-term neurodevelopmental outcomes was extremely limited. Most pre-therapeutic hypothermia studies demonstrated favorable short-term neurological or clinical outcomes. Studies conducted alongside therapeutic hypothermia have not reported long-term outcomes.
CONCLUSION: Postnatal MgSO₄ is safe and associated with improved short-term clinical outcomes in neonates with NE. However, absence of long-term benefit and limited evidence in the era of therapeutic hypothermia preclude routine clinical use.